# Performance of different nebulizers in clinical use for 1 Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) 2 3 Short title: Technical characterisation of PIPAC nebulizers 4 5 Daniel Göhler, Dipl.-Ing.<sup>1,2</sup>, Kathrin Oelschlägel, Dipl.-Ing<sup>1</sup>, Mehdi Ouaissi, Prof, MD, 6 PhD<sup>3,4</sup>, Urs Giger-Pabst, Prof, MD<sup>3,5</sup> 7 8 <sup>1</sup> Topas GmbH, Dresden, Germany 9 <sup>2</sup> Research Group Mechanical Process Engineering, Institute of Process Engineering and 10 Environmental Technology, Technische Universität Dresden, Dresden, Germany 11 <sup>3</sup> EA4245 Transplantation, Immunology, Inflammation, Université de Tours, France 12 <sup>4</sup> Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver 13 Transplant Surgery, University Hospital of Tours, France 14 15 <sup>5</sup> Fliedner Fachhochschule, University of Applied Science Düsseldorf, Düsseldorf, Germany 16 17 **Corresponding author:** 18 19 Urs Giger-Pabst, MD 20 University of Applied Science Fliedner Fachhochschule 21 22 Geschwister-Aufricht-Straße 9 40489 Düsseldorf, Germany 23 E-Mail: ursgiger@gmx.net 24 Phone: +49 163 729 44 07 25 26 27 **Kev words** 28 29 Pressurized Intraperitoneal Aerosol Chemotherapy, PIPAC, aerosol droplet size, gravimetry, $\label{eq:Nebulizer} \begin{array}{l} Nebulizer,\ MCR-4\ Topol^{\circledR},\ HurriChem^{TM},\ QuattroJet\\ \text{NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.} \end{array}$ 30

### Göhler et al. Final 14.03.2023

# **Author Contributions**

- 33 Daniel Göhler and Urs Giger-Pabst: study design, experiments, data acquisition, data
- interpretation and drafting of manuscript.
- 35 Kathrin Oelschlägel and Mehdi Ouaissi: critical revision for important intellectual content of
- 36 the manuscript according to their field of research.

# 37 **Disclosure**

32

- 38 Strictly academic study supported by institutional funds. All authors have no conflicts of
- 39 interest or financial ties to declare.

# 40 Data Availability Statement

- 41 All relevant data are within the manuscript. Raw data will be provided by the corresponding
- 42 author upon request.

# 43 Legal background

- Purely technical analyses without the use of biological material or patients requiring no specific
- 45 legal authorization or ethics vote.

# 46 Acknowledgments

50

- 47 The authors thank Professor Marc Pocard, Hepato-Biliary-Pancreatic Gastrointestinal Surgery
- and Liver Transplantation, Pitié Salpêtrière Hospital, AP-HP, F-75013 Paris, France, for
- 49 providing a HurriChem<sup>TM</sup> (ThermaSolutions, White Bear Lake, MN, USA) nozzle.

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Abstract Objective: Technical ex-vivo comparison of commercial nebulizer nozzles used for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). Methods: The performance of four different commercial nebulizer nozzles (Nebulizer; HurriChem<sup>TM</sup>; MCR-4 TOPOL<sup>®</sup>; QuattroJet) was analysed concerning: i) technical design and principle of operation, ii) operational pressure as function of the liquid flow rate, iii) droplet size distribution via laser diffraction spectrometry, iv) spray cone angle, spray cone form as well as horizontal drug deposition by image-metric analyses and v) chemical resistance via exposing to a cytostatic solution and chemical composition by means of spark optical emission spectral analysis. Results: The Nebulizer shows quasi an identical technical design and thus also a similar performance (e.g., mass median droplet size of 29 µm) as the original PIPAC nozzles (MIP/ CapnoPen). All other nozzles show more or less a performance deviation to the original PIPAC nozzles. The HurriChem<sup>TM</sup> has a similar design and principle of operation as the Nebulizer, but provides a finer aerosol (22 µm). The principle of operation of MCR-4 TOPOL® and QuattroJet differ significantly from that of the original PIPAC nozzle technology. The MCR-4 TOPOL® offers a hollow spray cone with significantly larger droplets (50 µm) than the original PIPAC nozzles. The QuattroJet generates an aerosol (22 µm) similar to that of the HurriChem<sup>TM</sup> but with improved spatial drug distribution. Conclusion: The availability of new PIPAC nozzles is encouraging but can also have a negative impact if their performance and efficacy is unknown. It is recommended that PIPAC nozzles that deviate from the current standard should be subject to bioequivalence testing and implementation in accordance with the IDEAL-D framework prior to routine clinical use.

#### Introduction 1

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

99

100

101

More than a decade ago, Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) was introduced clinically as a new approach to deliver intraperitoneal chemotherapy to patients suffering from end-stage peritoneal surface malignancies. Using a high-pressure injector connected to a specially designed PIPAC nozzle, liquid chemotherapeutic drugs are aerosolised during laparoscopic surgery within the capnoperitoneum. This approach is expected to have a better spatial distribution pattern, greater depth of penetration, and higher drug concentration in the tissue than conventional liquid intraperitoneal chemotherapy [1, 2]. Clinical data from phase I/II and larger mono- and multicentre case series regarding safety, feasibility, and oncologic efficacy are encouraging. While the therapeutic role of PIPAC is still unclear [3], prospective randomized PIPAC trials are underway and their results are eagerly awaited [4, 5]. For over a decade, only the original PIPAC nozzle was available for clinical use, with more than 18`000 documented clinical applications worldwide were projected by the end of 2022 [3]. To ensure comparability of the outcome data, much efforts was spent to standardize PIPAC therapy worldwide [6, 7]. But more recently, new nebulizer devices are also in clinical use. While the technical and clinical performance data of the original PIPAC nozzle has been extensively studied in pre- and clinical settings [3, 8, 9], no or only very limited comparative data are available for the new PIPAC nozzles. Oncological surgeons around the world are now faced with the question of whether these newer nozzles are equivalent to the original nozzle technology or perhaps even have technical/functional advantages with a potentially better

- On the basis of the methodological findings regarding the technical characterisation of the 96
- original PIPAC nozzle [8], the current study deals with the comparative performance 97
- characterisation of four commercial nebulizers as nowadays used for PIPAC. 98

#### **Materials and Methods** 2

oncological outcome?

#### 2.1 Examined PIPAC nozzles

- Four commercial single-substance PIPAC nozzles for intraperitoneal drug aerosolization were 102
- 103 examined, i.e.,
- 104 Nebulizer, Model 770-12, REGER Medizintechnik, Villingendorf, Germany (A),

#### Göhler et al. Final 14.03.2023

- HurriChem<sup>TM</sup>, ThermaSolutions, White Bear Lake, MN, United States of America (B),
- MCR-4 TOPOL®, SKALA-Medica, Sobĕslav, Czech Republic (C),
- QuattroJet, Model 770-14, REGER Medizintechnik, Villingendorf, Germany (D).
- After the experiments, all nozzles were cut-open longitudinally in the middle in a 180° angle
- by means of a computerized numerical control milling machine to study their principles of
- operation. In addition, also the dimensions of the nozzle outlet orifices were examined by light
- microscopy (SMZ1500, Nikon, Tokyo, Japan).

### 112 2.2 Barometric characterisation of operational pressure as function of liquid flow rate

- To characterise the operational pressure over the volumetric liquid flow rate, the nozzles were
- 114 connected via high-pressure hose lines with a high-pressure injector (ACCUTRON® HP-D,
- MEDTRON AG, Saarbrücken, Germany) to push the test liquid (Glucosterile 5%, Fresenius
- Kabi GmbH, Germany) through the nozzles. The operational pressure induced by the liquid
- 117 flow rate was determined by means of a glycerine-filled bourdon gauge (MA7U-25, JRA
- 118 Maschinenteile und Geräte GmbH, Reichenbach, Germany), which was implemented in the
- high-pressure line. For the analyses, the volumetric liquid flow rate was increased stepwise
- either by 0.1 ml/s (for nozzles A, B and D) or by 0.2 ml/s (for nozzle C) until the maximum
- permitted pressure of 21 bar of the high-pressure injector was reached. For nozzle D, only the
- axial nozzle was tested the horizontal nozzles were sealed watertight. Analogous to [8],
- measurement values were taken at steady state conditions of the aerosolization process and all
- analyses were repeated three times.

125

# 2.3 Granulometric characterisation of droplet size distributions

- The droplet size distributions of the aerosols generated from the test liquid (Glucosterile 5%,
- 127 Fresenius Kabi GmbH, Germany) were characterised by laser diffraction spectrometry
- 128 (PW180-C spray particle size analyser, Jinan K-Ring Technology Co., Ltd, Shandong, China)
- over a size range of (0.57 780) µm. The outlets of the PIPAC nozzles were arranged via a
- tripod in a distance of 5 mm perpendicular to the centre of the free-accessible red laser beam.
- To characterise the aerosolization performance, all analyses were performed contemporaneous
- with the barometric characterisation of the operational pressure for various liquid flow rates.
- Analogous to [8], measurement values were taken at steady state conditions of the
- aerosolization process and all analyses were repeated three times.

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

2.4 Image-metric characterisation of spray cone angles, form and horizontal drug deposition areas The spray cone angles, the form of the spray cones and the horizontal drug deposition area were characterised with different test liquids at nozzle-specific operation conditions as recommended by the manufacturers, i.e., at a volumetric liquid flow rate of 0.5 ml/s for the nozzles A, B, at 2.0 ml/s for nozzle C and 1.5 ml/s for nozzle D. The former two characteristics were evaluated on the base of a 5 wt.-% aqueous glucose solution (Glucosterile 5%, Fresenius Kabi GmbH, Germany), while the latter characteristic was assessed by operating the nozzles with undiluted royal blue ink (Pelikan Tinte 4001®, Hannover, Germany). For the spray cone angle analyses, the nozzles were fixed on a tripod and vertically aligned. Photographic images were taken with a camera that was perpendicular positioned to the nozzle direction. The images were in-silico processed by overlaying with a digital 360° full-circle protractor for determining the spray cone angles. The form of the spray cones was visualized by means of a line laser (GCL 2-15, Robert Bosch Power Tools GmbH, Leinfelden-Echterdingen, Germany) positioned in distance of 60 mm from the nozzle orifice at right angle into the spray cone. Fully evaluated spray cone forms were finally documented photographically. The horizontal drug deposition on a level-aligned blotting paper was examined by operating the vertically aligned nozzles with a distance of 60 mm between the blotting paper and the nozzle orifice. The blotting paper was exposed for 3 s to the fully-developed spray jet. To achieve this, a mechanical diaphragm was placed in front of the spray jet. The diaphragm was opened automatically within 0.1 s, when the aerosol jet showed steady state nebulisation condition. 2.5 Assessing of chemical resistance and chemical composition To assess the chemical resistance of the nozzle material against chemotherapeutic drugs, the nozzles were at first exposed to a cytostatic solution for 12 hours and afterwards stored in the dark at room temperature for 12 days within petri dishes. The chosen cytostatic solution was prepared in accordance to the mixture of high pressure/high dose PIPAC (HP/HD-PIPAC) [10], i.e., 6 mg of doxorubicin (Accord 2 mg/ml, Accord Healthcare GmbH, Munich, Germany) was admixed with 50 ml of a 0.9 wt.-% aqueous sodium chloride solution (Ecolav® 100, B. Braun, Melsungen, Germany). Finally, the nozzles were milled open in a laminar flow workbench and macroscopic changes were documented photographically.

### Göhler et al. Final 14.03.2023


Moreover, the chemical composition of the nozzles pipes was characterised for the elements C, Si, Mn, P, S, Cr, Ni, Mo, Cu, W and N by means of spark optical emission spectral analysis (SPECTROMAXX, SPECTRO Analytical Instruments GmbH, Kleve, Germany) via an accredited laboratory (WS Material Service GmbH, Essen, Germany).

# 3 Results

# 3.1 Technical design and principle of operation

The 90° sectional views of the head regions in Figure 1 show technical destails of the examined nozzles.

# A (Nebulizer) B (HurriChem<sup>™</sup>) C (MCR-4 TOPOL®) D (QuattroJet)



**Figure 1:**  $90^{\circ}$  sectional views of the head regions of the nozzles. Legend: O = outlet orifice; H = nozzle head; I = bar inlay with distal transverse borehole; M = double metal grid; N = fixed needle; S = shaft; T = twist body.

Externally, all nozzles consist of a stainless steel shaft (S) with a more or less pronounced nozzle head (H) on the lower part and a Luer lock thread on the upper part (not shown in Figure 1). The Luer lock threads serve for the connection of the nozzles with high-pressure injectors via high-pressure hose lines. Internally, the nozzles show partly considerable differences.


#### Göhler et al. Final 14.03.2023

Interestingly, nozzle A and B are quasi identical in construction and their principle of operation, while the nozzles C and D differ significantly from them and from each other.

In the case of the nozzles A, B and D, the liquid drug is supplied internally from the Luer lock connector to the nozzle head via an annular gap between the outer shaft (S) and a bar inlay with distal transverse borehole (I). In contrast, the internal liquid drug supply of nozzle C occurs directly via the hollow cavity of the shaft (S). Moreover, nozzle C is equipped with a double metal grid (M) with two different mesh sizes that serve as particle filter.

While the nozzles A and B contain one twist body (T), nozzle D is equipped with four twist bodies (i.e., with one axial and three lateral twist bodies in 120° arrangement) to improve the spatial drug distribution within the abdominal cavity. The twist bodies (T) of the nozzles A, B and D contain longitudinally superfically milled grooves at 180° intervals. As the liquid drug flow rate passes along the twist bodies (T) they were set into rotation that improves the aerosolisation prior leaving the nozzle via the outlet orifice (O). In the case of nozzle C, the twist body is replaced by an fixed metal needle (N). This needle contains also laterally located, spirally milled axial grooves that induce a whirlwind effect for aerosolisation when passed by the liquid flow before leaving the nozzle via the outlet orifice (O).

Light microscopic images of the oulet orifices (O) with determined orifice diameters of the examined nozzles are shown in Figure 2.



**Figure 2:** Light microscopic images of the outlet orifices with determined orifice diameters of the examined nozzles; scaling in mm.

#### 3.2 Operational parameters based on barometric and granulometric analyses

Figure 3 a depicts at first the determined operational pressure over the liquid flow rate of the examined nozzles, while in Figure 3 b the mass median diameter of the of the droplet size distribution over the operational pressure is given. To avoid artefacts due clouding of the optics

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223


224

225

226

227

of the laser diffraction spectrometer, the lateral nozzles of nozzle D (QuattroJet) were taped off for the granulometric analyses and a flow rate of 0.5 ml/s was chosen (manufacturerrecommended flow rate of 1.5 ml/s) Note that the shown data are determined at steady state conditions of the aerosolization process analogous to [8]. It can be observed in Figure 3 a that the determined operational pressure data for all examined nozzles fit well with the fluid dynamic theory, i.e., the dynamic pressure (or the dynamic pressure drop) of an incompressible fluid increases with the fluid velocity by the power of two. According to the equation of continuity, the fluid velocity of an incompressible fluid is in turn directly proportional to the volumetric liquid flow rate. The nozzles A, B and D show a similar performance regarding operational pressure and liquid flow rate, while nozzle C (MCR-4 TOPOL®) has a significantly lower pressure drop and thus a considerable higher volumetric liquid flow rate at a specific operational pressure. Beside the whole operational spectrum, also the manufacturer-recommended operational conditions were separately examined, i.e., at a volumetric liquid flow rate of 0.5 ml/s for nozzle A (Nebulizer), nozzle B (HurriChem<sup>TM</sup>), (1.3 - 2.0) ml/s for nozzle C (MCR-4 TOPOL®) and 1.5 ml/s for nozzle D (QuattroJet). Under these preconditions nozzle C showed with (18 - 26) s the shortest initiation time to reach the corresponding steady state pressure of (7.4 - 18.1) bar, followed by nozzle A with 52 s (15.7 bar) and nozzle D with 94 s (16.0 bar). Note that with taped-off lateral nozzles, nozzle D shows a higher operational pressure of 19.3 bar (as shown in Figure 3).



**Figure 3:** Operational pressure as function of the liquid flow rate from barometric analyses (a), mass median diameter as function of the operational pressure from granulometric analyses (b) and volume-weighted distributions density (c) and cumulative distribution (d) of droplets at certain manufacturer-recommended operational condition; black cycles/ellipses indicate manufacturer-recommended operation condition.

Figure 3 b shows that the mass median diameter of the generated droplet aerosols depends for each nozzle significantly on the operational pressure. With increasing operational pressure, the mass median diameter decreases. For operational pressures of  $\leq 4$  bar, quasi no significant difference between the different nozzles can be observed. This is attributed to a non-fully developed aerosolization of the supplied liquid. For operation pressures of  $\geq 5$  bar stable aerosol


### Göhler et al. Final 14.03.2023

generation is reached and differences between the nozzles can be observed. For operational pressures  $\geq 5$  bar, nozzle C (MCR-4 TOPOL®) shows the coarsest mass median diameters, followed by nozzle A (Nebulizer). The finest mass median diameters were determined for nozzle B (HurriChem<sup>TM</sup>) and D (QuattroJet).

This ranking can also be deduced by the volume-weighted droplet size distributions of the aerosols as generated by the nozzles at the manufacturer-recommended operation conditions (Figure 3 c, Figure 3 d). Moreover, it can be observed in Figure 3 c and Figure 3 d, that each aerosol has a polydisperse and bimodal droplet size distribution.

# 3.3 Operational parameters based on image-metric analyses

Figure 4 shows photographic images for the spray cone angle (upper panel), the spray cone form (mid panel) and the horizontal drug deposition area (lower panel) of each examined nozzle as determined at manufacturer-recommended operational conditions.



#### Göhler et al. Final 14.03.2023

**Figure 4:** Photographic images of spray cone angle (upper panel), of spray cone form (middle panel) and horizontal drug deposition area (lower panel, scale in cm).

According to the upper panel of Figure 4, the widest single spray cone angle was determined with 79° for nozzle C (MCR-4 TOPOL®), followed with 72° for nozzle A (Nebulizer) and with 71° for nozzle B (HurriChem<sup>TM</sup>). Nozzle D (QuattroJet) shows with 67° the smallest single spray cone angel, but it has to keep in mind that nozzle D contains in contrast to the other nozzles of four spray cones. Moreover, it can be observed from the middle panel of Figure 4 that nozzle A (Nebulizer), nozzle B (HurriChem<sup>TM</sup>) and nozzle D (QuattroJet) generate a full spray cone, whereas nozzle C (MCR-4 TOPOL®) produces a hollow spray cone. The full spray cones of the nozzles A, B and C lead also to complete filled circular areas of horizontal drug deposition beneath the nozzles as shown in the lower panel of Figure 4. In the case of the nozzles A and B, a circular deposition area of approx. 38.5 cm² (outer diameter of approx. 7 cm) was determined. The lateral outlets of nozzle D showed beside the axial circle (outer diameter of approx. 7 cm) also 3 additional deposition areas of (13 × 20) cm that cumulates to an overall horizontal deposition area of approx. 679 cm².

# 3.5 Chemical resistance and chemical composition

Photographic images of the nozzle parts after the exposure to the cytostatic solution are shown in Figure 5.



**Figure 5:** Photographic images of the nozzle parts after exposure to the cytostatic solution.

Figure 5 shows that in the case of nozzle C (MCR-4 TOPOL®) the exposure to the cytostatic solution led to the formation of iron oxide. These are particularly pronounced on the fine-mesh particle filter, the nozzle needle and the nozzle head housing. No changes were observed for the nozzles A, B and D either visually or by light microscopic analyses.

The nozzles A, B and D fulfil all requirements according to EN 10088-3:2014 [11] on the chemical composition of stainless steel 1.4301 that is typically used for surgical instruments.

Beside a twelve times higher quantity of sulphur (0.012 wt.-% vs. 0.001wt.-%), also quantities of molybdenum (0.183 wt.-%), copper (0.220 wt.-%) and tungsten (0.134wt.-%) were identified by spark optical emission spectrometry for nozzle C (MCR-4 TOPOL®).

#### 4 Discussion

Due to the current lack of knowledge, four clinically-operated nebulising nozzles for PIPAC were comparatively tested regarding their performance. The most important determined technical characteristics of these nozzles are summarised in Table 1.

**Table 1:** Overview on technical and functional characteristics of the examined nozzles; \* = manufacturer-recommended operational conditions.

parameter	unit	A (Nebulizer)	B (HurriChem <sup>TM</sup> )	C (MCR-4 TOPOL®)	D (QuattroJet)
*liquid flow rate (*QL)	ml/s	0.5	0.5	1.3 - 2.0	1.5
operational pressure for *QL	bar	15.7	14.9	7.4 - 18.1	16.0
pressure initiation time for *QL	s	52	100	18 - 26	94
nozzle orifice diameter	μm	200	190	370	170
mass median diameter for 15 bar	μm	28.95	20.99	52.17	24.18
max. spray angle for *QL	0	≈ 72	≈ 71	≈ 79	≈ 67
number of nozzles	-	$1 \times axial$	$1 \times axial$	$1 \times axial$	$1 \times \text{axial}, 3 \times \text{lateral}$
kind of spray cone	-	full cone	full cone	hollow cone	full cone
drug deposition area for *QL	cm <sup>2</sup>	≈ 38.5	≈ 38.5	≈ 66	≈ 679

Nozzle A (Nebulizer) shows after an initiation time of 52 s an operational pressure of 15.7 bar at the manufacturer-recommended operational liquid flow rate of 0.5 ml/s. Thereby, a full spray jet cone (71°) composed of droplets with a mass median diameter of 29  $\mu$ m is formed. The determined data of this study reveal that nozzle A is identical in design and performance to the primary for PIPAC developed predecessor, i.e., the microinjection pump MIP [8], which was also distributed under the tradename CapnoPen.

Nozzle B (HurriChem<sup>TM</sup>) is another launched nebulizer for PIPAC. Examinations on design and principle of operation show a high similarity with nozzle A (Nebulizer) and thus also with the initial PIPAC nozzle technology. At the manufacturer-recommended operational liquid flow rate of 0.5 ml/s, nozzle B shows after an initiation time of 100 s an operational pressure of

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

14.9 bar. The mass median diameter of the droplets in the formed full spray jet cone (73°) was determined to be 21 µm. Nozzle C (MCR-4 TOPOL®) differs in technical design, principle of operation, operational parameter and aerosol characteristics significantly from all other investigated nozzles. The operation of nozzle C is accompanied by the formation of a hollow spray cone jet (79°). At the manufacturer-recommended operational liquid flow rate range of (1.3 - 2.0) ml/s, operational pressures of (7.4 - 18.1) bar were reached within short initiation times of (18 - 26) s. The mass median droplet size decreases with increasing liquid flow rate, but was found to be in each case larger than 50 µm. Nozzle D (QuattroJet) is a further PIPAC nebulizing nozzle that was introduced by the manufacturer of nozzle A. To optimize the spatial drug distribution pattern and higher intraabdominal aerosol particle concentration, the conventional axial nozzle is supplemented in nozzle D by three further nozzles, which are arranged lateral at the nozzle head with an angular distance of 120°. Nozzle D is based on the same technology as nozzle A. At the manufacturerrecommended flow rate of 1.5 ml/s, nozzle D shows an operational pressure of 16.0 bar after an initiation time of 92 s and provides four full spray cone jets (67°) composed of droplets with a mass median diameter of 21 µm. Recently, a first attempt regarding recommendations on the minimum technical requirements on nozzles suitable for PIPAC treatment was published. A minimum requirement for the spray angle of at least 70° was defined [12] by implying that the spray cone angle corresponds to the achievable drug deposition area. But there are two limitations found in this study that contradict this requirement. The present study shows that the requirement is matched directly by nozzle A, B and C. But despite of a slightly lower spray cone angle of 67° than required, nozzle D consists of four spatially-displaced spray jets cumulating in a total spray angle of 268°. On the other hand, Nozzle C, unlike all other nozzles examined, had a hollow spray cone, resulting in a ring-shaped drug deposition area that was smaller than that of a full spray cone jet at the same spray cone angle. With regard on the nozzle performance, the drug deposition area seems to be an even better technical parameter than the spray cone angle. The examined nozzles C (MCR-4 TOPOL®) and D (QuattroJet) of this study show in contrast to A (Nebulizer) and B (HurriChem<sup>TM</sup>) and thus in contrast to the primary PIPAC nozzle technology significant differences in their principle of operation and performance. Nozzle C

#### *Göhler et al. Final 14.03.2023*

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

offers the largest spray cone angle of all examined nozzles, but also a hollow spray cone. It is not evident if such a spray jet improves drug distribution and drug penetration, since so far as known there are no preclinical studies comparing a hollow with a full spray cone. Nozzle D provides multiple spray cones that can significantly improve the spatial drug distribution by reduction of high local deposition and thus high local tissue toxicity. Nonetheless, these potential benefits of multi-nozzle systems need to be confirmed by further research. A worrying result of this study was, that nozzle C (MCR-4 TOPOL®) shows in contrast to the other nozzles a macroscopically visible formation of iron oxide after long-term exposure in a sodium chloride containing cytostatic solution. Based on spark optical emission spectrometry, it was found that this nozzle was made from a steel that, in addition to a 12-fold higher sulphur content (0.012 wt.-\% vs. 0.001 wt.-\%), also contained amounts of molybdenum (0.183 wt.-\%), copper (0.220 wt.-%) and tungsten (0.134 wt.-%). Short-term exposure of the nebulizers to cytostatic solution shows no immediate corrosion, but a possible risk for the patient cannot be completely ruled out. This leads to the conclusion that manufacturer and regulatory authorities for medical devices accreditation must also critically assess the suitability of specific steel alloys for the administration of cytostatic drugs in their risk assessment. Currently, there are only limited preclinical data to suggest that there is an optimal technique for the generation and delivery of PIPAC aerosols that could improve clinical outcome. However, it is clear that, contrary to claims made by one manufacturer [13], larger aerosol droplets injected into the peritoneal cavity at higher velocities with a hollow spray cone do not improve either the spatial distribution pattern [8, 14] or tissue penetration depth per se. Nebulizers differing from the present standard technology in its design, especially in its spraying characteristics, cannot automatically be considered equivalent by the clinical user. Therefore, before their broad clinical use, the individual innovation phases should be systematically tested, ideally following the recommendation of the IDEAL-D framework for the introduction of medical devices [15, 16]. While the original nozzle technology has completed phase I - IIb [17] and phase III trials are ongoing [4, 5], only limited phase I clinical user data has been published for nozzle C (MCR-4 Topol®) [18]. Such data are lacking for nozzle B and D. In the near future, clinical users should be able to rely on technical testing and reporting being based on scientific standards and generally applicable global standards, such as ISO standards. For PIPAC nebulizers, such standards should ideally be set by a panel of experts through

consensus conferences. Moreover, nebulizers with significant technical and granulometric differences from the standard technology should undergo first ex- and in-vivo animal testing before their first clinical use. Manufacturers should be obliged to have the bioequivalence of the cytostatic drugs administered independently certified in comparison to standard nebulizer systems, analogous to drugs and their generics. Relevant outcome measures are aerosol characteristics, spatial drug distribution, depth of penetration, tissue concentration and the peak concentration and the area under the curve describing the extent of peritoneal passage [8, 19 -28]. The ratio between the individual properties of the generic nebulizer and the reference product would ideally be 1:1 in case of bioequivalence. Since this is unlikely to be achieved, the US Food and Drug Administration (FDA), for example, requires that the 90% confidence interval should be between 0.80 and 1.25 [29]. Similar to the FDA specifications, new PIPAC nozzle technologies could be tested comparatively in the future. Such preclinical testing, ideally using standardized models, could prevent the use of such devices from compromising clinical outcomes and/or harming healthcare professionals/patients. Finally, it would be helpful for the comparability of clinical results if the nebulizer type used in each case will be also recorded in the PIPAC database (https://isspp.org/professionals/pipac-database/).

#### 5 Conclusion

Four clinically-used nozzles to aerosolise chemotherapeutic drugs in the context of Pressurized 380

Intraperitoneal Aerosol Chemotherapy (PIPAC), i.e., the Nebulizer, the HurriChem<sup>TM</sup>, the

MCR-4 TOPOL® and the QuattroJet were examined comparative to determine their

performance.

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

381

382

383

384

385

386

387

388

389

390

391

392

393

It could be confirmed that the Nebulizer shows quasi an identical technical design and thus also a similar performance as the original PIPAC nozzles MIP/CapnoPen. The PIPAC nozzle HurriChem<sup>TM</sup> is based on a similar technical design as the Nebulizer nozzle, but provides a finer aerosol due to a smaller nozzle orifice opening. Both, the MCR-4 TOPOL® and the QuattroJet deviate in the principles of operations to that of the Nebulizer and thus to the original PIPAC technology. While the MCR-4 TOPOL® provides the coarsest aerosol of all examined nozzles, the QuattroJet delivers an aerosol similar to that of the HurriChem<sup>TM</sup>. In contrast to the HurriChem<sup>TM</sup>, the QuattroJet<sup>®</sup> comes with the feature of four spray cones (one axial, three lateral) to improve the spatial drug distribution and a higher aerosol particle number

#### Göhler et al. Final 14.03.2023

The availability of new PIPAC nozzles with special features is encouraging, but can also have a negative impact for establishment of the promising PIPAC approach for the treatment of peritoneal carcinomatosis, if their performance and efficacy is unknown. It is therefore recommended that nozzles for which the technical/granulometric characteristics differ from the current standard technology must be subjected to preclinical proof of equivalence in terms of spatial drug distribution, tissue penetration and concentration before routine clinical use. It is expected that representative in-silico models like the ones used in [23, 24] will be available in the near future. New nebulizers should be investigated and introduced for clinical use in accordance with the IDEAL-D framework.

# References

404

- 1. Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA Description of a novel 405
- approach for intraperitoneal drug delivery and the related device. Surg. Endosc. 406
- 2012;26(7):1849–1855. Doi: 10.1007/s00464-012-2148-0. 407
- 2. Solaß W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal 408
- carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence 409
- for efficacy. Ann. Surg. Oncol. 2014;21(2):553–559. Doi: 10.1245/s10434-013-3213-1. 410
- 3. Alyami M, Hübner M, Grass F, et al. Pressurised intraperitoneal aerosol chemotherapy: 411
- rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368–e377. Doi: 412
- 10.1016/S1470-2045(19)30318-3 413
- 4. Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC Pressurized IntraPeritoneal Aerosol 414
- 415 Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases
- secondary to platinum resistant ovarian cancer study protocol for a randomized control 416
- 417 trial. Pleura and Peritoneum 2019;4(1). Doi: 10.1515/pp-2018-0111
- 5. Casella F, Bencivenga M, Rosati R, et al. Pressurized intraperitoneal aerosol chemotherapy 418
- (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: 419
- a randomized multicenter phase III trial PIPAC VEROne. Pleura and Peritoneum 420
- 2022;7(3):135–141. Doi: 10.1515/pp-2022-0111 421
- 6. Sgarbura O, Villeneuve L, Alyami M, et al. Current practice of pressurized intraperitoneal 422
- aerosol chemotherapy (PIPAC): Still standardized or on the verge of diversification? 423
- European Journal of Surgical Oncology 2021;47(1):149–156. 424 Doi:
- 10.1016/j.ejso.2020.08.020 425
- 7. Sgarbura O, Eveno C, Alyami M, et al. Consensus statement for treatment protocols in 426
- pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura and Peritoneum 427
- 2022;7(1):1–7. Doi: 10.1515/pp-2022-0102 428
- 8. Göhler D, Khosrawipour V, Khosrawipour T, et al. Technical description of the micro 429
- injection pump (MIP®) and granulometric characterization of the aerosol applied for 430
- IntraPeritoneal Aerosol Chemotherapy (PIPAC). Endosc. 431 Surg.
- 2017;31(4):1778–1784. Doi: 10.1007/s00464-016-5174-5 432
- 9. Nadiradze G, Horvath P, Sautkin Y, et al. Overcoming Drug Resistance by Taking 433
- 434 Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy
- (PIPAC). Cancers 2020;12(1):34. Doi: 10.3390/cancers12010034. 435

- 436 10. Arias GR, Sindayigaya R, Ouaissi M, et al. Safety and Feasibility of High-Pressure/High-
- Dose Pressurized Intraperitoneal Aerosol Chemotherapy (HP/HD-PIPAC) for Primary and 437
- Metastatic Peritoneal Surface Malignancies. Ann. Surg. Oncol. 2022. Doi: 10.1245/s10434-438
- 022-12698-4. 439
- 440 11. EN 10088-3:2014. Stainless steels - Part 3: Technical delivery conditions for semi-finished
- products, bars, rods, wire, sections and bright products of corrosion resisting steels for 441
- general purpose. 442
- 12. Pocard M, So JBY, Huchon C, et al. PIPAC nebulizer: How to test the new devices in the 443
- 444 expert recommendations. Journal of Visceral Surgery 2022. Doi:
- 10.1016/j.jviscsurg.2022.10.001. 445
- 13. PIPAC Pressurized Intraperitoneal Aerosol Chemotherapy; https://www.skala.cz/en/mcr-446
- 4-topol-en/ (access: 5th March 2023 at 11:02 CET) 447
- 14. Hinds, William C. (1999). Aerosol technology: properties, behaviour, and measurement of 448
- airborne particles. New York: Wiley. ISBN 978-0-471-19410-1. 449
- 15. Sedrakyan A, Campbell B, Merino JG, Kuntz R, Hirst A, McCulloch P IDEAL-D: a rational 450
- framework for evaluating and regulating the use of medical devices. Br. Med. J. 2016:i2372. 451
- 452 Doi: 10.1136/bmj.i2372.
- 16. Páez A, Rovers M, Hutchison K, Rogers W, Vasey B, McCulloch P Beyond the RCT: When 453
- are Randomized Trials Unnecessary for New Therapeutic Devices, and What Should We 454
- 455 Do Instead? Ann. Surg. 2021;275(2):324–331. Doi: 10.1097/SLA.000000000005053.
- 17. Baggaley AE, Lafaurie GBRC, Tate SJ, et al. Pressurized intraperitoneal aerosol 456
- 457 chemotherapy (PIPAC): updated systematic review using the IDEAL framework. Br. J.
- Surg. 2022;110(1):10–18. Doi: 10.1093/bjs/znac284. 458
- 18. Hoskovec D, Dytrych P, Vocka M, Krska Z, Skala R MCR-4 TOPOL® new device for 459
- PIPAC first clinical use. Eur. J. Surg. Oncol. 460 2022;48(2):e155.
- 10.1016/j.ejso.2021.12.308. 461
- 19. Rahimi-Gorji M, Debbaut C, Ghorbaniasl G, Cosyns S, Willaert W, Ceelen W Optimization 462
- of Intraperitoneal Aerosolized Drug Delivery: A Computational Fluid Dynamics (CFD) and 463
- Experimental Study. Scientific Reports 2021;12(1). Doi: 10.1038/s41598-022-10369-8. 464
- 20. Göhler D, Geldner A, Gritzki R, et al. Development of a rat capnoperitoneum phantom 465
- (RCP) to study drug aerosol deposition in the context of anticancer research on peritoneal 466
- carcinomatosis. Sci. Rep. 2021;11:21843. Doi: 10.1038/s41598-021-01332-0. 467

- 21. Göhler D, Große S, Bellendorf A, et al. Hyperthermic intracavitary nano-aerosol therapy 468
- (HINAT) as improved approach for pressurised intraperitoneal aerosol chemotherapy 469
- (PIPAC): Technical description, experimental validation and first proof of concept. 470
- Beilstein J. Nanotechnol. 2017;8:2729–2740. Doi: 10.3762/bjnano.8.272. 471
- 472 22. Buggisch JR, Göhler D, Sobilo J, et al. Development and technical validation of an
- ultrasound nebulizer to deliver intraperitoneal pressurized aerosols in a rat colon cancer 473
- peritoneal metastases model. BMC Cancer 2022;22(570). Doi: 10.1186/s12885-022-09668-474
- 0. 475

498

- 23. Rezniczek GA, Buggisch J, Sobilo J, et al. Establishment of a mouse ovarian cancer and 476
- peritoneal metastasis model to study intraperitoneal chemotherapy. Cancers 2020;12(12). 477
- Doi: 10.3390/cancers12123818. 478
- 24. Höltzcke P, Sautkin I, Clere S, Castagna A, Königsrainer A, Pott PP, Reymond MA. 479
- Feasibility of pressurized intra peritoneal aerosol chemotherapy using an ultrasound aerosol 480
- generator (usPIPAC). Surg Endosc. 2022 Oct;36(10):7848-7858. doi: 10.1007/s00464-022-481
- 09525-y. Epub 2022 Aug 29. PMID: 36038646; PMCID: PMC9485099. 482
- 25. Toussaint L, Sautkin Y, Illing B, Weinreich FJ, Nadiradze G, Königsrainer A, Wichmann 483
- D. Correction to: Comparison between microcatheter and nebulizer for generating 484
- 485 Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Surg Endosc. 2021
- Aug;35(8):4901. doi: 10.1007/s00464-021-08577-w. Erratum for: Surg Endosc. 2021 486
- Apr;35(4):1636-1643. PMID: 34106308; PMCID: PMC8263410. 487
- 26. Mun J, Park SJ, Kim HS. Rotational intraperitoneal pressurized aerosol chemotherapy in a 488
- 489 porcine model. Gland Surg. 2021 Mar;10(3):1271-1275. doi: 10.21037/gs-2019-ursoc-11.
- PMID: 33842275; PMCID: PMC8033043. 490
- 27. Mimouni, M., Richard, C., Adenot, P. et al. Pressurized intra-peritoneal aerosol 491
- chemotherapy (PIPAC): increased intraperitoneal pressure does not affect distribution 492
- 493 patterns but leads to deeper penetration depth of doxorubicin in a sheep model. BMC Cancer
- 21, 461 (2021). https://doi.org/10.1186/s12885-021-07955-w 494
- 28. Giger-Pabst, U., Bucur, P., Roger, S. et al. Comparison of Tissue and Blood Concentrations 495
- of Oxaliplatin Administrated by Different Modalities of Intraperitoneal Chemotherapy. Ann 496
- Surg Oncol 26, 4445–4451 (2019). https://doi.org/10.1245/s10434-019-07695-z 497

29. Andrade C Bioequivalence of Generic Drugs: A Simple Explanation for a US Food and 499

Drug Administration Requirement. Journal of Clinical Psychiatry 2015;76(06):e742-e744. 500

Doi: 10.4088/JCP.15f10094. 501